CorMedix (NASDAQ:CRMD) Shares Down 4.6% – Here’s Why

CorMedix Inc (NASDAQ:CRMD) shares traded down 4.6% on Friday . The company traded as low as $7.70 and last traded at $7.7680. Approximately 271,047 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 1,719,592 shares. The stock had previously closed at $8.14.

More CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix reported Q2 revenue of $101.9 million, above the roughly $96 million analyst consensus, while adjusted EBITDA reached $58.7 million and net income was $26.0 million. EPS of $0.29 also exceeded expectations. Growth was supported by continued DefenCath utilization and contributions from the Melinta portfolio. CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
• Positive Sentiment: Management maintained its FY 2026 revenue outlook of $325 million to $345 million and raised adjusted EBITDA guidance, reinforcing expectations for strong profitability and operating leverage. CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company expects to submit a supplemental filing for its fungal-disease treatment by the third quarter. Progress on this regulatory opportunity could provide an additional growth catalyst beyond DefenCath. CorMedix CEO expects supplemental filing for fungal disease treatment by Q3
• Neutral Sentiment: Brokerages currently assign CorMedix an average “Moderate Buy” recommendation, indicating generally favorable sentiment but not a uniformly bullish analyst view. CorMedix Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Although the revenue outlook’s midpoint is broadly in line with consensus, investors may be taking profits or reassessing valuation after the initial earnings-driven rally. The stock remains below its 50-day moving average, adding to near-term volatility.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Royal Bank Of Canada lifted their price objective on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of CorMedix in a report on Monday, April 27th. Leerink Partners raised their price target on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research note on Tuesday. Finally, Zacks Research upgraded shares of CorMedix from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 2.97 and a quick ratio of 2.74. The company has a 50-day moving average price of $8.16 and a 200-day moving average price of $7.65. The firm has a market capitalization of $607.12 million, a PE ratio of 3.65 and a beta of 1.50.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $101.93 million for the quarter, compared to analyst estimates of $96.04 million. CorMedix had a return on equity of 45.57% and a net margin of 45.25%. Sell-side analysts forecast that CorMedix Inc will post 0.51 EPS for the current year.

Institutional Investors Weigh In On CorMedix

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of CorMedix in the second quarter valued at approximately $49,644,000. Deerfield Management Company L.P. acquired a new stake in CorMedix during the third quarter worth approximately $38,656,000. Marshall Wace LLP boosted its position in CorMedix by 34.6% during the third quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after acquiring an additional 893,518 shares during the last quarter. UBS Group AG grew its stake in CorMedix by 295.3% in the 3rd quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock worth $12,687,000 after acquiring an additional 814,964 shares during the period. Finally, Jump Financial LLC purchased a new stake in CorMedix in the 3rd quarter worth approximately $9,003,000. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.